Peter M Neupert sold $3.1M of ADPT
director at Adaptive Biotechnologies Corp. 124,690 shares at an average of $25.15, traded Aug 17, 2026, filed Aug 19, 2026.
Score components
- +15RoleDirector
- +25Trade size$3.1M at market
- +10Share of holdings soldSold 49% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001237566-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | MOption exercise Common Stock | +15,000 | $6.32 | $95k | 255,315 | Aug 19, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock | -15,000 | $25.23 | $378k | 240,315 | Aug 19, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock | -40,000 | $25.10 | $1.0M | 200,315 | Aug 19, 2026 |
| Aug 17, 2026 | SOpen-market sale Common Stock | -69,690 | $25.16 | $1.8M | 130,625 | Aug 19, 2026 |
| Aug 17, 2026 | MOption exercise Stock Option (right to buy)derivative | -15,000 | $0.00 | $0 | 0 | Aug 19, 2026 |
Related signals
Other insiders at Adaptive Biotechnologies Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $948k 35,643 shares | -9% | |
| 22Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $193k 6,444 shares | -2% | |
| 22Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $758k 26,792 shares | -11% | |
| 25Weak | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $1.0M 35,643 shares | -9% | |
| 23Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $3.2M 115,406 shares | -34% | |
| 8Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $32k 1,195 shares | -0% | |
| 48Moderate | Adaptive Biotechnologies Corp | Katey Einterz Owen director | $250k 9,615 shares | -11% | |
| 46Moderate | Adaptive Biotechnologies Corp | Robert Hershberg director | $748k 30,664 shares | -40% | |
| 55Moderate | Adaptive Biotechnologies Corp | Chad M Robins CEO and Chairman | $15M 600,000 shares | -24% | |
| 18Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $75k 3,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.